Lung Cancer
Phase II trial of GV1001 in lung cancer started
Published in Cancer Weekly, January 9th, 2007
The trial is an investigator sponsored trial, designed and led by Krefklinikken, Rigshospital-Radiumhospitalet in Olso in collaboration with St. Olav's Hospital in Trondheim. Pharmexa has agreed to supply GV1001 for the trial, which is partly funded by Norges Forskningsred (the Norwegian Research Council).
The trial is an open label exploratory Phase II trial in patients with stage IIIA and stage IIIB non-small cell lung cancer. In the trial, GV1001 together with the adjuvant GM-CSF is tested in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-01-09)
More Articles from Cancer Weekly
- Cancer Research
Run amok enzyme causes the same problems in both humans and fruit flies - Cancer Therapy
Allergy drug slows pancreatic tumor growth, enhances chemotherapy in preclinical studies - Cancer Therapy
Introgen announces new clinical data confirming Advexin survival benefit - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at Fudan University, Department of Pharmaceutics - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at Central Hospital - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at University of Medicine - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
